This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dr. Peter C. Neligan, Author Of 3rd Edition Of Elsevier's Plastic Surgery Text, Available For Comment On The Contributions Of Dr. Joseph Murray

PHILADELPHIA, Nov. 27, 2012 /PRNewswire/ -- In the wake of the passing of Nobel Prize winning surgeon Dr. Joseph Murray, who carried out the first successful kidney transplant in 1954, Dr. Peter C. Neligan, author of the definitive textbook of the discipline, Plastic Surgery , ( 3 rd Ed., Elsevier, October 2012 ) is available to comment on Dr. Murray's legacy of innovation. Dr. Murray died on Monday in Boston at the age of 93.

"The history of Plastic Surgery is one of innovation in medicine, and Dr. Murray's contributions paved the way for developments that today continue in areas such as hand and face transplantation," says Dr. Neligan, author of five books, more than 50 book chapters and 170 peer-reviewed papers.

A professor of Plastic Surgery and Otolaryngology/Neck Surgery at the University of Washington Medical Center in Seattle, Dr. Neligan spent four years editing Plastic Surgery, working with the Elsevier team and with the volume editors. The 6-volume text is the first update in a decade, and includes 160 videos and online resources that bring the latest techniques to the practitioner's iPad or cell phone.

"Many people think of plastic surgery as a cosmetic practice, but Aesthetic Surgery fills only one of the six volumes in the Plastic Surgery text," Dr. Neligan says. "Plastic Surgeons are leading the way with new developments in stem cell therapy, tissue engineering, and inductive therapies; aesthetic surgical techniques and nonsurgical treatments; conjoined twin separation and other craniofacial surgery advances; microsurgical lymphatic reconstruction, super microsurgery, nerve transfers in hand surgery, functional prosthetics, and more."

Additional information about Dr. Neligan and Plastic Surgery is available at http://elsevierauthors.com/peterneligan.

SOURCE Elsevier, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,745.98 -5.41 -0.03%
S&P 500 2,108.63 +0.06 0.00%
NASDAQ 5,128.7850 +17.0520 0.33%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs